# Case Study: Psilocybin and MDMA-Assisted Therapy

**Query:** What is the current clinical trial evidence for psilocybin therapy for depression and MDMA-assisted therapy for PTSD? Summarize the phase II/III trial results, effect sizes, and regulatory status.

**Domain:** psychedelics
**Sources:** Semantic Scholar, PubMed
**Model:** opensynthesis/Qwen3-14B-heretic
**Date:** 2026-02-21

---

## Synthesis

Clinical trials evaluating psilocybin therapy for depression and MDMA-assisted therapy for PTSD have yielded compelling results, supported by both phase II and III trials, indicating significant therapeutic potential for these conditions.

For **psilocybin therapy** targeting **depression**, multiple phase II and III trials have demonstrated its efficacy. Psilocybin acts primarily through the serotonin 5-HT2A receptor, enhancing neuroplasticity and brain connectivity, resulting in rapid and sustained symptom relief [SOURCE 1]. A systematic review of seven randomized-controlled trials (RCTs) involving 522 participants found that psilocybin-assisted therapy (PAT) produced a large and significant antidepressant effect, with greater efficacy observed when psilocybin was administered in bodyweight-adjusted doses and when combined with extended preparation, dosing, and integration sessions alongside non-manualized psychotherapy [SOURCE 6]. Additionally, early studies suggest that psilocybin may be superior to escitalopram in treating MDD and effective for PTSD and treatment-resistant depression [SOURCE 5]. Notably, psilocybin's rapid onset of action -- within hours rather than weeks -- makes it particularly suitable for patients like those with head and neck cancer (HNC), who require quick relief from depressive symptoms post-surgery [SOURCE 5].

Regarding **MDMA-assisted therapy** for **PTSD**, phase II trials revealed that 54% of participants receiving full-dose MDMA no longer met the PTSD diagnosis after two sessions, compared to 23% in the control group [SOURCE 2]. Subsequent phase III trials confirmed these findings, with 67% of participants no longer meeting PTSD criteria after three sessions, and these effects remained stable over time, with 67% still meeting criteria at one year and 74% at nearly four years [SOURCE 2]. A pivotal phase III RCT (NCT03537014) reported that MDMA-assisted therapy led to a significant reduction in PTSD symptoms, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), with a mean change in CAPS-5 scores of -24.4 in the MDMA group versus -13.9 in the placebo group (P < 0.0001, d = 0.91) [SOURCE 9]. Furthermore, the treatment was associated with a notable reduction in functional impairment, as indicated by the Sheehan Disability Scale (SDS), with a mean change of -3.3 in the MDMA group versus -2.1 in the placebo group (P = 0.03, d = 0.4) [SOURCE 18]. These results were consistent across diverse populations, including those with comorbid conditions such as dissociation, depression, and a history of alcohol and substance use disorders [SOURCE 9].

Effect sizes for both psilocybin and MDMA therapies are substantial. For example, in PTSD, the standardized mean difference (SMD) for MDMA-assisted therapy compared to controls was -0.85, indicating a large effect size [SOURCE 11]. Similarly, psilocybin therapy has shown effect sizes exceeding those of conventional antidepressants, with acute-phase effect sizes often more than double those seen with standard treatments [SOURCE 15].

Regulatory advancements reflect the growing acceptance of these therapies. Psilocybin has been the subject of legislative efforts, such as Hawaii's Senate Bill 738 in 2021, aiming to remove it from the Schedule I controlled substances list [SOURCE 2]. Meanwhile, MDMA-assisted therapy received breakthrough therapy designation from the FDA in 2017 and is now under consideration for approval, with the FDA voting against its approval in 2024 due to concerns regarding trial design and safety assessments [SOURCE 3]. Nonetheless, ongoing research continues to refine methodologies, addressing issues such as blinding and long-term safety, which are crucial for regulatory acceptance [SOURCE 3].

Despite these promising findings, some methodological limitations exist. For instance, high rates of functional unblinding in psilocybin trials, coupled with participant expectations, may introduce bias [SOURCE 15]. Additionally, while MDMA-assisted therapy shows promise, concerns about trial design, including blinding failures and incomplete safety assessments, have been noted [SOURCE 3]. Moreover, the evidence for psilocybin in bipolar depression remains preliminary, with early studies showing encouraging results but persistent safety concerns such as affective switching and pharmacokinetic interactions [SOURCE 10].

In summary, clinical trial evidence supports the efficacy of psilocybin therapy for depression and MDMA-assisted therapy for PTSD, with robust effect sizes observed in phase II and III trials. Regulatory progress is underway, though challenges related to trial design and safety assessments remain. Future research should focus on confirming these findings in larger, more diverse populations and addressing methodological limitations to ensure the generalizability and sustainability of these therapeutic approaches.

### Falsifiability Criteria

Evidence that would contradict this synthesis includes:
- Psilocybin therapy does not lead to significant improvements in depression symptoms in larger, adequately powered phase III trials
- MDMA-assisted therapy fails to produce meaningful reductions in PTSD symptoms across diverse patient populations
- Subsequent trials fail to replicate the observed effect sizes
- Significant adverse events emerge that outweigh therapeutic benefits
